German company SCHOTT Pharma will further expand in the U.S. with a new syringe manufacturing facility in Wilson, N.C. The $371 million project is expected to break ground by the end of the year, with operations scheduled to start in 2027.
Wilson County was selected for its access to the Research Triangle and its labor pool. North Carolina supported SCHOTT’s expansion with $21 million in local and state incentive awards.
The project marks the first facility to manufacture prefillable polymer syringes that will meet the need for deep-cold storage and mRNA medications transportation. The facility will also produce glass prefillable syringes designed for GLP-1 therapies that treat diseases such as obesity or diabetes.
READ ALSO: Manufacturing’s Comeback Boosts Industrial Space Demand
SCHOTT expects to triple its U.S. production of glass and polymer syringes by 2030. The company’s products average to about 25,000 injections delivered per minute and serves around 1,800 customers globally.
Partners on the project also include the North Carolina Department of Commerce, the Economic Development Partnership of North Carolina, the North Carolina Community College System and the Wilson Economic Development Council.
Biomanufacturing sector’s growth in N.C.
High-tech industries have generated two-thirds of new manufacturing jobs over the past three years in the U.S., according to a new manufacturing report from Savills. North Carolina continues to attract biomanufacturing and pharmaceutical industries, with 9 percent of the new jobs created in the state between 2021 and 2023 being part of this sector.
A recent significant investment was FUJIFILM’s $2 billion life science facility in Holly Springs, N.C. The 1 million-square-foot property is expected to come online in 2025 and generate 725 manufacturing jobs. In late 2023, Johnson & Johnson’s Janssen Supply Group became the first tenant at the development.
